comparemela.com
Home
Live Updates
QurAlis Receives Clinical Trial Authorisation (CTA) in the U
QurAlis Receives Clinical Trial Authorisation (CTA) in the U
QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
/PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS)...
Related Keywords
United Kingdom ,
Germany ,
Cambridge ,
Cambridgeshire ,
Netherlands ,
Belgium ,
Canada ,
Ireland ,
Spain ,
Barcelona ,
Comunidad Autonoma De Cataluna ,
Angela Genge ,
Kasper Roet ,
Kevin Eggan ,
Healthcare Products Regulatory Agency ,
European Union ,
Eggan Lab ,
European Network To Cure ,
Prnewswire Quralis Corporation ,
Alis Corporation ,
Clinical Trial Application ,
Therapeutic Section ,
European Network ,
Trial Authorisation ,
Quralis ,